Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | USP5 | P45974 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27685278 | 0.83 | BDKRB2 (0.38) | KMT2AOPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL10280046 | 0.83 | L3MBTL1 (0.33) | KMT2AOPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL8948627 | 0.79 | OPRM1 (0.41) | OPRM1OPRD1OPRK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10567744 | 0.78 | KMT2A (0.58) | KMT2AOPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL15232200 | 0.78 | KMT2A (0.42) | KMT2AOPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL3019549 | 0.78 | — | — | |
| SCHEMBL25447273 | 0.78 | CYP2C19 (0.36) | KMT2AOPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL25566055 | 0.78 | KMT2A (0.50) | KMT2ACYP1A2TDP1SMN1; SMN2HTR1A | |
| SCHEMBL29889358 | 0.78 | ALDH1A1 (0.39) | KMT2AOPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL10232812 | 0.78 | CYP2D6 (0.38) | OPRM1OPRD1OPRK1KCNH2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| CN-112513024-A | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| CN-1897946-A | 1- 2' (1, 4'-biperidin-1'-yl)-1- (phenyl) -ethyl cyclohexanol derivatives as monoamine reuptake modulators for the treatment of visomotor symptoms | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| US-4447434-A | ANTIULCER, ANTISECRETORY, OR ANTICHOLINERGIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-05-08 | — | — | US | disclosed |
| US-4424225-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| US-4424226-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0085892-A1 | Substituted benzodiazepinones, process for their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0085899-A2 | Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | KMT2A 1574/4885OPRM1 4106/4885SLC22A1 2762/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KMT2A 1065/4885OPRM1 539/4885SLC22A1 2633/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | KMT2A 2825/4885OPRM1 4577/4885SLC22A1 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.